Biotechnologies have been presented with great emphasis in the public arena, since their fi rst applications, as "one of the most promising frontiers of contemporary science" (Il Sole 24 ore 26/09/99). Th eir use has allowed the development of products in various fi elds and proposed as relevant "facts". In medicine, insulin has been produced, in vitro embryos have been created, and prenatal and pre-implant in utero diagnoses have been perfected. In agriculture, with the production of herbicides and pesticides together new plant varieties, there has been an increase in crop productivity. With regard to animals, the characteristics of several species have been improved by overcoming the barriers between them with recombinant DNA technology, and the cloning of several animal types.
Achievement of these goals and the promotion of the advantages promised by biotechnologies have been fl anked by a parallel growth in uncertainties concerning their eff ects on humans and the environment. In particular, the biotechnologies applied to human and vegetable cells have provoked various controversies, especially in the case of GMOs, which, with regard to agriculture and the agro-food industry, have caused great alarm among the public. Th ese concerns are due, in a general sense, to the potentials of biotechnologies: they allow life (human, animal and vegetable) to be changed in a way which thirty years ago was unimaginable, thereby posing situations with uncertain outcomes (Callon 1999; Wynne 1999) .
Th ere are other specifi c reasons for these suspicions. Th e ability of scientists to modify nature and life using biotechnologies, beginning with the discovery of DNA, has created great expectations in governments and the economic and fi nancial spheres for example, the launching of large-scale research programmes like the genome project. Th is work has mostly been carried out by private industry, highlighting the self-serving side of science ever more attentive to economic results and therefore to the monopoly in certain innovations, illustrated by taking out patents.
Th is interest in the use of biotechnologies in the agriculture and agro-food sector has produced an industrial concentration made up of a small number of multinational companies with monopolies on the main patents allowing the use of GMOs in agricultural production. Th ese economic aspects have roused public suspicions, especially when the innovations concern goods for consumption, i.e. food products, for which, especially in the western world, no pressing need is seen. As in the case of other techno-scientifi c innovations, the world of science is unable to provide political decision-makers with exhaustive safety guarantees on the use of biotechnologies (Pellizzoni 2005) , given that the consequences of their application are not easily quantifi able, and there is a lack of studies on the environmental impact.
2 Public opinion is not solely interested in the analysis and evaluation of potential risks according to scientifi c parameters. It is also interested in ethical and moral factors tied with trust in the regulatory system (Salter & Frewer 2001) . Various opinion polls on GMOs, for example, have demonstrated that they are perceived as threats because they are "unnatural" products with which the idea of an unjustifi ed risk is associated. Consequently, it is impossible to refer solely to accurate risk assessments in order to reassure the public; social values must also be considered. If, for example, an emphasis is placed on the benefi ts for human health, the environment, and fauna, perceptions of risk might be counterbalanced, but only if the requests made for these benefi ts are realistic (Frewer et al. 1997) .
Th ese studies demonstrate the diffi culties encountered by the scientifi c world in meeting the demands of public opinion, given that science oft en responds to ethical and moral issues in terms of risk assessment. For this reason, proponents of the scientifi c community have on several
